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Initial Paclitaxel Improves Outcome Compared With CMFP
Combination Chemotherapy as Front-Line Therapy
in Untreated Metastatic Breast Cancer
By James F. Bishop, Joanna Dewar, Guy C. Toner, Jennifer Smith, Martin H.N. Tattersall, Ian N. Olver, Stephen Ackland,
Ian Kennedy, David Goldstein, Howard Gurney, Euan Walpole, John Levi, Jennifer Stephenson, and Renzo Canetta
for the Taxol Investigational Trials Group, Australia/New Zealand
Purpose: To determine the place of single-agent pacli-
taxel compared with nonanthracycline combination
chemotherapy as front-line therapy in metastatic breast
cancer.
Patients and Methods: Patients with previously un-
treated metastatic breast cancer were randomized to
receive either paclitaxel 200 mg/m2 intravenously (IV)
over 3 hours for eight cycles (24 weeks) or standard
cyclophosphamide 100 mg/m2/d orally on days 1 to
14, methotrexate 40 mg/m2 IV on days 1 and 8,
fluorouracil 600 mg/m2 IV on days 1 and 8, and predni-
sone 40 mg/m2/d orally on days 1 to 14 (CMFP) for six
cycles (24 weeks) with epirubicin recommended as
second-line therapy.
Results: A total of 209 eligible patients were random-
ized with a median survival duration of 17.3 months for
paclitaxel and 13.9 months for CMFP. Multivariate analy-
sis showed that patients who received paclitaxel sur-
vived significantly longer than those who received CMFP
(P 5 .025). Paclitaxel produced significantly less severe
leukopenia, thrombocytopenia, mucositis, documented
infections (all P F .001), nausea or vomiting (P 5 .003),
and fever without documented infection (P 5 .007), and
less hospitalization for febrile neutropenia than did
CMFP (P 5 .001). Alopecia, peripheral neuropathy, and
myalgia or arthralgia were more severe with paclitaxel
(all P F .0001). Overall, quality of life was similar for
both treatments (P H .07).
Conclusion: Initial paclitaxel was associated with
significantly less myelosuppression and fewer infec-
tions, with longer survival and similar quality of life and
control of metastatic breast cancer compared with CMFP.
J Clin Oncol 17:2355-2364. r 1999 by American
Society of Clinical Oncology.
IN THE UNITED STATES each year, more than 180,000women are diagnosed with breast cancer and more than
45,000 die of the disease.1 Despite the major advances in
adjuvant therapy, metastatic breast cancer remains a major
clinical problem that affects large numbers of patients. For
many years, standard chemotherapy combinations have been
the mainstay of therapy for metastatic disease that is
hormone resistant, estrogen receptor–negative, or with life-
threatening or visceral disease. Initial chemotherapy has
been either combinations of cyclophosphamide, methotrex-
ate, fluorouracil, and prednisone (CMFP) followed by
anthracycline, or doxorubicin-containing combinations.2-4
The choice of an appropriate initial chemotherapy is often
limited by early relapse in patients who recently received
adjuvant chemotherapy with the same combinations or by
the condition of the patient. Thus, it is important to define
the place of new anticancer drugs in breast cancer therapy.
When first described by Cooper,5 CMFP-like combina-
tions were reported with high response rates. When assessed
using modern criteria and increasingly sophisticated imag-
ing procedures, the CMFP regimen with or without vincris-
tine produced objective responses in 37% to 68% of patients
and median durations of response ranging from 6 to 11
months, with an associated median survival duration from
initiation of treatment of 7 to 16 months.6-15
Doxorubicin alone has been shown to be as active as
CMFP combinations in randomized studies in advanced
breast cancer.2,8,16 In these studies, doxorubicin produced
shorter response duration when used as a single agent, but
there was no clear difference in survival. Survival is difficult
to interpret in these studies because patients were usually
crossed over to the alternative regimen on progression.
Of six randomized studies that compared combinations of
cyclophosphamide, doxorubicin, and fluorouracil with CMFP
combinations in advanced breast cancer, three showed
significantly higher response rates with the combination of
cyclophosphamide, doxorubicin, and fluorouracil.17-23 How-
ever, only two of six studies showed a statistically significant
survival advantage for the doxorubicin combination. These
studies have been interpreted as showing a slight advantage
for doxorubicin combinations in metastatic breast cancer.17
A recent meta-analysis of chemotherapy trials for metastatic
breast cancer reviewed trials that compared anthracycline-
versus nonanthracycline-based regimens.24 Anthracycline
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combinations had higher response rates, but overall survival
rates were similar. CMFP has been used as front-line therapy
for metastatic breast cancer after early relapse from anthra-
cycline-based adjuvant therapy, in the debilitated patient
where palliation is the goal of therapy or by patient choice
on consideration of side effects.
In an Australian randomized study, the combination of
doxorubicin and cyclophosphamide was compared with
CMFP in 305 previously untreated patients with metastatic
breast cancer.12 The response, response duration, and sur-
vival were similar between CMFP and doxorubicin/
cyclophosphamide administered continuously until relapse.
The doxorubicin combination was associated with signifi-
cantly more nausea, vomiting, and alopecia compared with
the CMFP combination. This experience provided an addi-
tional rationale for the use of CMFP as the control arm for
our phase III randomized trial of CMFP compared with
paclitaxel alone. CMF is a widely used combination in the
adjuvant as well as the advanced setting, especially for good
prognosis patients. Thus, the results of this comparison may
have wider implications.
Paclitaxel is a novel cytotoxic agent that binds to the
beta-tubulin monomer, inducing permanent microtubular
polymerization.25,26 The loss of dynamic reorganization of
microtubules during mitosis results in selective block in the
G2/M phase of cell division. This action in vitro correlates
with clinical activity.27 Paclitaxel as a 24-hour infusion is
active in previously untreated patients with advanced breast
cancer.28-33 The duration of paclitaxel infusion has varied,
with other studies reporting 3-hour infusion schedules or,
since our study was started, 1-hour infusions.34-37 A large
randomized European-Canadian study compared two doses
of paclitaxel (135 mg/m2 v 175 mg/m2) and two infusion
times (3 hours v 24 hours) in relapsed ovarian cancer. There
was no difference in outcome detected between the two
doses or infusion rates. The incidence of hypersensitivity
reactions on this study was low and not influenced by the
dose or schedule. However, this study clearly demonstrated
that the 24-hour paclitaxel infusion was associated with a
significantly greater reduction in neutrophils after each
course compared with the 3-hour infusion.34 This observa-
tion has been confirmed by another recent randomized study
that compared 3-, 6-, and 24-hour infusions.38 On the basis
of this evidence and its convenience, the 3-hour schedule
was chosen for this trial. Subsequently, a randomized phase
III trial of 3- versus 96-hour infusions of paclitaxel has
demonstrated no differences in outcomes in metastatic
breast cancer.39
At the time this trial was initiated, it was unclear whether
the dose of paclitaxel was important in metastatic breast
cancer. However, early studies reported high response rates
at 200-mg/m2 and 250-mg/m2 doses of paclitaxel as a
24-hour infusion, providing a rationale for the paclitaxel
dose of 200 mg/m2 for this trial.40,41 Subsequently, Nabholtz
et al42 suggested that a 175-mg/m2 dose of paclitaxel may
prolong time to progression compared with a dose of 135
mg/m2.
PATIENTS AND METHODS
Patients
Eligible patients with histologically proven metastatic or locally
advanced breast cancer (stage III or IV) or recurrent breast cancer after
surgery, prior radiotherapy more than 4 weeks previously, or prior
adjuvant chemotherapy more than 6 months earlier, but no prior
chemotherapy for advanced disease, were entered onto the trial.
Requirements included an Eastern Cooperative Oncology Group (ECOG)
performance status of 0 to 2; disease measurable or assessable for
response; adequate prior bone marrow, liver, and renal function; a life
expectancy of at least 3 months; and written informed consent. Patients
not eligible for the trial were those with a history of or current
malignancy other than breast cancer, except nonmelanoma skin cancer
or carcinoma-in-situ of the cervix, a history of cardiac arrhythmias,
congestive cardiac failure, documented myocardial infarction within the
prior 6 months, World Health Organization (WHO) grade 2 or worse
neuropathy, proven brain metastasis as sole evidence of metastasis, or
dementia or altered mental status that would prohibit informed con-
sent.43
Ethics Review
The protocol was approved by the institutional ethics committees of
each participating institution. Written informed consent was obtained
for each patient. All serious adverse reactions were reported to the study
sponsor and to institutional ethics committees in accordance with their
reporting requirements. The study was designed, conducted, analyzed,
and reported in accordance with the Guidelines for Good Clinical
Research Practice (GCRP) in Australia.44
Toxicity and Response Criteria
Standard WHO toxicity and response criteria were used.43 Quality of
life (QOL) was assessed using QOL linear analog scales completed by
the patient and the Spitzer QOL index completed by the physician.12,45
Treatment
Patients were stratified by institution and randomized to receive
either paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ) 200
mg/m2 intravenously (IV) infused over 3 hours every 21 days for eight
courses (24 weeks) or cyclophosphamide 100 mg/m2/d orally on days 1
to 14, methotrexate 40 mg/m2 IV on days 1 and 8, fluorouracil 600
mg/m2 IV on days 1 and 8, and prednisone 40 mg/m2/d orally on days 1
to 14 repeated every 28 days for six courses (24 weeks; Fig 1). Patients
who received paclitaxel were given premedication with dexamethasone
20 mg orally 12 hours and again 6 hours before chemotherapy.
Diphenhydramine 50 mg IV (or promethazine 25 mg) and cimetidine
300 mg IV (or ranitidine 50 mg IV) were administered 30 minutes
before chemotherapy. Antiemetics were subsequently administered at
the investigator’s discretion. Patients whose disease progressed while
receiving front-line therapy were recommended to receive epirubicin 90
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mg/m2 IV every 3 weeks. After 6 months of initial chemotherapy,
patients with stable disease or objective response were to be monitored
off therapy until relapse.
Dose Modification
Dose modifications were based on nadir counts, with 25% dose
reductions for absolute neutrophil count less than 0.5 3 109/L, platelet
count less than 50 3 109/L, and/or febrile neutropenia (fever . 38°C
with absolute neutrophil count , 0.5 3 109/L) or significant thrombocy-
topenic bleeding. Patients with an absolute neutrophil count less than
1.5 3 109/L or a platelet count less than 100 3 109/L at scheduled
re-treatment dates were required to have a weekly delay until recovery
with dose adjustment based on nadir counts.
All WHO grade 3 nonhematologic toxicities (except alopecia and
nausea/vomiting) required 25% dose reduction. Any patient who
experienced WHO grade 4 nonhematologic toxicity was to be taken off
study. Patients with symptomatic arrhythmia or atrioventricular block
were to cease treatment. Patients with hypersensitivity reactions with
hypotension, angioedema, respiratory distress, or generalized urticaria
were to have their paclitaxel infusion stopped and hypersensitivity
medically managed.
Investigations
Scheduled investigations included complete blood examination,
which was performed before treatment and weekly thereafter. Urea
analysis, electrolyte analysis, liver function tests, WHO toxicity rating,
physical examination, and QOL assessments were performed before
treatment and subsequently with each course of treatment. Investiga-
tions to establish and monitor metastatic disease included computed
tomography scan, bone scan, and radiographs before therapy, with tests
repeated after 12 weeks and 24 weeks on therapy. These tests were also
repeated at the time of suspected relapse or progression and at intervals
no less than 4 weeks apart when confirming a partial or complete
response. After completion of treatment, patients were monitored
monthly until relapse, and thereafter their status was obtained at
3-month intervals until death or study analysis.
Statistical Methods
The target accrual was 200 patients. Patients were stratified by
participating center before randomization. Computer-generated random-
ization charts were prepared for each center and held at the Statistical
Centre at Peter MacCallum Cancer Institute, Melbourne, Australia.
Randomization was based on an adaptive biased coin procedure with a
bias of 3n at each allocation in favor of the arm with n fewer patients. All
data were collected by institutional data managers, checked by sponsor-
ing company monitors and at the trial center, and entered on a database
at the Statistical Centre.
One planned interim analysis was conducted after 23 patients were
accrued to each arm to check that the response rate was at least 25% for
each treatment arm. The results were not released to the investigators. A
second interim analysis was conducted on the first 100 patients for a
conference presentation, but this took place after completion of accrual
of all patients onto the trial. The emerging data from this analysis,
therefore, would not have affected either the accrual or the interpreta-
tion of the final results of the trial.
All major end points were compared using intention-to-treat analyses
that included all randomized patients. Response rates in the two arms
were compared using a two-sided Fisher’s exact test with StatXact 3 for
Windows (Cytel Software Corp, Cambridge, MA). Progression-free and
overall survival rates were estimated according to the Kaplan-Meier
product-limit method, using S-PLUS version 3.3 for Windows (StatSci,
Seattle, WA). Time was measured from the date of randomization and
the close-out date for all survival analyses was February 20, 1997. All
deaths were counted as events in the overall survival analyses, and both
progressions and deaths without progression in the progression-free
survival curves. The Brookmeyer-Crowley method was used to estimate
95% confidence intervals for median survival times. Differences
between groups were tested using the Mantel-Cox log-rank test
(S-PLUS version 3.3 for Windows).
Categories of toxicity were compared between the two randomization
arms using the Cochran-Armitage test for linear trend with exact
inference, two-sided, unless otherwise specified (StatXact 3 for Win-
dows). Disease sites were classified into skin and soft tissue, bone, liver,
lung (including pleural effusions), and other visceral (including brain).
Prognostic factors were tested in univariate analyses of response,
progression-free survival, and overall survival. These included ECOG
performance status, extent of disease, menopausal status at diagnosis,
time since diagnosis, prior adjuvant chemotherapy, prior radiotherapy,
and prior hormone therapy. Multivariate analyses were performed on
the aforementioned factors plus randomization arm, using logistic
regression for analysis of response (LogXact for Windows; Cytel) and
the Cox proportional hazards model for survival analyses (SPSS
Advanced Statistics 7.5, SPSS Inc, Chicago, IL).
QOL was assessed before the commencement of treatment and after
each course. The QOL instruments were those previously published and
validated by many of the investigators in this study.12,45 At each
assessment, the patient marked six linear analog scales (physical
well-being, mood, pain, nausea/vomiting, appetite, overall QOL), and
the physician completed the Spitzer QOL index that consisted of five
questions, each scored 1 to 3. The Wilcoxon rank sum test was used to
compare the treatment arms for the average improvement in each
measure of QOL while on treatment relative to the baseline values.46
RESULTS
A total of 209 patients were accrued from 17 centers in
Australia and New Zealand: 107 were randomized to receive
paclitaxel, and 102 were randomized to receive CMFP. The
median age of patients was 54 years on both arms (ranges:
paclitaxel, 36 to 73 years; CMFP, 32 to 80 years).
Patient characteristics at randomization are listed in Table
1. At trial entry, 31% of patients on the paclitaxel arm and
40% of patients on the CMFP arm had an ECOG perfor-
mance status of 0. Only 21% of paclitaxel patients and 33%
Fig 1. Treatment schema.
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of CMFP patients had received prior adjuvant chemother-
apy. Five completed their adjuvant therapy between 9 and 12
months, and the remainder more than 12 months before
randomization. Seventy-two percent of paclitaxel patients
and 77% of CMFP patients had received prior endocrine
therapy. The trial opened for accrual in September 1993, and
the median follow-up for patients still alive at the close-out
date was 26 months (range, 17 to 40 months).
Two paclitaxel patients and three CMFP patients did not
receive any of their randomized treatment. Dose reductions
of more than 5% occurred in 23% of treated paclitaxel
patients and 32% of CMFP patients. Nine percent of
paclitaxel patients had a delay of $ 1 week, whereas 34% of
CMFP patients experienced a similar delay. Forty-eight
percent of paclitaxel patients and 52% of CMFP patients
completed 24 weeks of treatment.
Complete response occurred in 2% of paclitaxel patients
and 6% of CMFP patients. Partial response occurred in 27%
of paclitaxel patients and 29% of CMFP patients. The
overall objective response rates for paclitaxel and CMFP
were 29% (95% confidence interval [CI], 21% to 39%) and
35% (95% CI, 26% to 45%), respectively (P 5 .37; Table 2).
Stable disease was noted in 37% of patients who received
paclitaxel and 32% who received CMFP. Potential prognos-
tic factors were studied to determine whether they influ-
enced response rates. Only patients who were premeno-
pausal at diagnosis had significantly higher response rates
than peri/postmenopausal women (P 5 .008). However,
there was still no significant difference between treatment
arms (P 5 .44) when adjusted for menopausal status in a
multivariate logistic regression model. No other on-study
factors had a significant influence on response rates. The
response rate of CMFP patients who had received prior
adjuvant CMF was not significantly different from those
who had not (P 5 .66).
Only 4% of paclitaxel patients and 3% of CMFP patients
were alive without progression at the close-out date. The
estimated median time to progression for paclitaxel patients
was 5.3 months (95% CI, 4.1 to 5.6 months), with 15%
progression-free at 1 year and 3% at 2 years. The estimated
median time to progression for CMFP patients was 6.4
months (95% CI, 5.2 to 7.8 months), with 17% progression-
free at 1 year and 5% at 2 years. There was no significant
difference between the treatment arms (P 5 .25; Fig 2 and
Table 2). Univariate analyses of prognostic factors that affect
progression-free survival showed that patients with an
ECOG performance status of 0 (P 5 .024) or more than 3
years since diagnosis (P 5 .002) had significantly longer
Table 1. Patient Characteristics at Randomization by Treatment Arm
% Paclitaxel
(n 5 107)
% CMFP
(n 5 102)
ECOG performance status
0 31 40
1 60 48
2 9 12
Site of disease*
Skin/soft tissue 53 51
Bone 65 58
Liver 46 47
Lung 40 39
Other visceral 13 11
Dominant site of disease
Skin/soft tissue only 7 14
Bone 6 skin/soft tissue 18 16
Visceral 6 bone 6 skin/soft tissue 75 71
Menopausal status at diagnosis
Premenopausal 47 48
Peri/postmenopausal 52 52
Unknown 1 0
Time since diagnosis, years
# 3 47 50
. 3 53 50
Estrogen receptor status
Positive 40 37
Negative or borderline 30 19
Unknown 30 44
Progesterone receptor status
Positive 29 25
Negative or borderline 34 21
Unknown 37 54
Prior adjuvant chemotherapy
None 79 67
CMF (vincristine) (prednisolone) 21 29
CMF (doxorubicin) 0 1
Other 0 2
Unknown 0 1
Other prior therapy*
Adjuvant radiotherapy 39 48
Palliative radiotherapy 42 39
Endocrine therapy 72 77
*Each patient could have more than one site.
Table 2. Summary of Results by Treatment Arm
Paclitaxel
(n 5 107)
CMFP
(n 5 102)
P% 95% CI % 95% CI
Response rate
(complete 1 partial) 29 21-39 35 26-45 .37
Progression-free survival
Estimated median (months) 5.3 4.1-5.6 6.4 5.2-7.8
Surviving progression-free at
1 year 15 8-22 17 9-24 .25
Surviving progression-free at
2 years 3 0-8 5 1-9
Overall survival
Estimated median (months) 17.3 12.6-21.4 13.9 11.4-16.5
Surviving at 1 year 61 52-70 55 45-65 .068
Surviving at 2 years 39 29-48 20 12-29
6
6
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progression-free survival. In the multivariate model that
contained these two factors, there remained no significant
difference between the treatment arms (P 5 .23).
There were 30% of paclitaxel patients and 20% of CMFP
patients still alive at the close-out date. The estimated
median survival duration was 17.3 months (95% CI, 12.6 to
21.4 months) for paclitaxel patients with 61% alive at 1 year
and 39% at 2 years. The estimated median survival of CMFP
patients was 13.9 months (95% CI, 11.4 to 16.5 months),
with 55% alive at 1 year and 20% at 2 years. The difference
between the two treatment arms was not statistically signifi-
cant (P 5 .068; Fig 3 and Table 2).
Univariate analysis of on-study factors showed that
patients with an ECOG performance status of 0 (P 5 .002),
nonvisceral disease (P 5 .0003), or diagnosis more than 3
years before randomization (P 5 .002), had significantly
better survival. For example, patients with an ECOG perfor-
mance status of 0 had a median survival duration of 20.0
months compared with only 12.6 months for patients with a
performance status of 1 or 2. Multivariate analysis con-
firmed the importance of these factors (Table 3). In this
model, patients on the initial paclitaxel arm had significantly
improved survival compared with those on the CMFP arm
(P 5 .025). There were no important interactions between
the three significant prognostic factors and the treatment
arms.
Leukopenia, thrombocytopenia, nausea and vomiting, and
mucositis were all significantly less severe with paclitaxel
compared with CMFP (Table 4). Febrile neutropenia and/or
infection occurred in 10% of paclitaxel patients and 27% of
CMFP patients (P 5 .001). The mean duration of admission
for febrile neutropenia or infection was 1.5 days for
paclitaxel and 4.4 days for CMFP (P 5 .0006). Overall,
1.6% of paclitaxel courses and 8.2% of CMFP courses
required hospitalization for febrile neutropenia and/or docu-
mented infection. Alopecia, myalgia/arthralgia, and periph-
eral neuropathy were significantly more severe with pacli-
taxel compared with CMFP (P , .0001). WHO grade 3
peripheral neuropathy occurred in 9% of paclitaxel patients,
and grade 4 occurred in 1%. Only three patients experienced
hypersensitivity reactions with hypotension while receiving
paclitaxel treatment and without sequelae.
QOL was assessed at study entry and after every treatment
course. The average QOL over all courses was calculated
and subtracted from the baseline value. Both the patient’s
and physician’s assessment of QOL were recorded. Most
measures of QOL (except pain) were slightly better with
paclitaxel than with CMFP, but the differences were not
statistically significant (P $ .07 for all measures; Fig 4).
Thirty-three patients who received initial paclitaxel and
31 who received CMFP underwent no further chemotherapy
(Table 5). Similar numbers of patients on both arms received
second-line anthracycline (43 paclitaxel patients; 39 CMFP
patients). An objective response to second-line anthracycline-
based chemotherapy occurred in 33% of patients on the
paclitaxel arm and 21% on the CMFP arm. Patients who
initially received paclitaxel with anthracycline second-line
chemotherapy had an estimated median survival duration of
Fig 2. Progression-free survival
by treatment arm.
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13.3 months from the initiation of second-line chemother-
apy, whereas patients who originally received CMFP had an
estimated median survival duration of 5.5 months. Because
the selection of patients for second-line therapy was subject
to bias, statistical comparison was not performed on these
two outcomes.
DISCUSSION
These results show that initial paclitaxel alone produces
tumor control comparable to that with CMFP combination
chemotherapy, with similar objective response and time to
progression. The response rate for paclitaxel is similar to
those previously reported for single-agent paclitaxel admin-
istered as a 3-hour infusion. The response rate for CMFP
seems low but is within the range previously reported in the
literature, and the 95% CI for response to CMFP in this trial
suggests that the objective response rate is between 26% and
45%. The response rates may reflect the more intensive and
sophisticated imaging techniques applied in modern cancer
trials and the difficulty in discerning change in bone lesions.
Perhaps more importantly, the median time to progression
and survival on CMFP is similar to that previously reported
with this combination in Australia and elsewhere.2-4,6-14
In the univariate analysis, overall survival was slightly
longer on the paclitaxel arm, but the difference was not
statistically significant (P 5 .068). The trial randomization
was stratified by institution but not for each of the seven
potential prognostic factors, three of which were shown to
have a significant influence on survival in this trial. Adjust-
ing for these factors, Cox proportional hazards regression
showed that patients on the paclitaxel treatment arm had
significantly improved survival (P 5 .025). The prolonga-
tion of survival seemed to be clinically meaningful, with a
median survival duration of 17.3 months with paclitaxel and
13.9 months with CMFP, and a relative death rate (paclitaxel/
CMFP) of 0.70 after adjustment for prognostic factors. This
improvement in survival seemed to be of value to patients,
with a 19% improvement in survival at 2 years. However,
because the initial tumor control rates are similar, the
improvement in survival may reflect a more optimal se-
quence of therapy starting with paclitaxel.
Weekly blood counts were obtained to provide an accu-
rate picture of the comparative myelosuppression of the two
arms. Paclitaxel caused significantly less leukopenia and
thrombocytopenia. Neutropenia was similar between the
two arms, whereas the number of infections, hospitalization
Fig 3. Overall survival by treat-
ment arm.
Table 3. Cox Proportional Hazards Model of Factors That Influence Survival
Factor
Reference
Group
Relative
Death Rate
PEstimate 95% CI
# 3 years since diagnosis . 3 years 2.0 1.4-2.8 , .0001
ECOG performance status 1-2 0 2.0 1.4-2.8 .0001
Visceral disease Nonvisceral 2.0 1.3-2.9 .0003
Paclitaxel CMFP 0.7 0.5-1.0 .025
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for infection, and duration of hospitalization were much less
with paclitaxel than with CMFP. A possible explanation is
that CMFP was associated with significantly more mucosi-
tis, thus providing a portal of entry of infection. In addition,
the duration of neutropenia with paclitaxel was considerably
shorter, as indicated by the number of patients who required
treatment delays. Alopecia, myalgia, and peripheral neuropa-
thy were significantly more pronounced with paclitaxel. The
latter was grade 3 or 4 in only 10% of patients.
Overall, the QOL on both arms seemed acceptable to
patients and was not significantly different. Patients were
asked to score overall QOL on both treatments and would
have considered general tolerance of the side effects as well
as symptoms related to disease. With the exception of pain,
patients on the paclitaxel arm experienced slightly better
QOL for each parameter during treatment than patients on
the CMFP arm.
Although this trial is the first comparison of paclitaxel
monotherapy and CMFP as front-line chemotherapy for
metastatic disease, the preliminary results of two other trials
help to put this trial in context.47-49 Sledge et al48 from the
ECOG compared single-agent paclitaxel at 175 mg/m2 over
24 hours with doxorubicin and the combination of doxorubi-
cin plus paclitaxel in a randomized trial in previously
untreated patients with metastatic breast cancer. In that
study, the objective response rate for paclitaxel monotherapy
was 34%, and the median time to progression was 6 months.
Their results are similar to the results reported in our study.
In the ECOG trial, comparison of the two single agents,
paclitaxel and doxorubicin, produced similar response, time
to progression, and survival. However, cross-over occurred
on both monotherapy arms.
Fig 4. Average changes in QOL
relative to baseline by treatment arm.
Table 4. Comparison of Acute Toxicities Between Treatment Arms*
Worst WHO Grade†
% of Patients
With Each Grade
P0 1 2 3 4
Leukopenia
Paclitaxel 11 18 42 23 6 , .0001
CMFP 4 12 17 42 24
Neutropenia
Paclitaxel 8 9 17 28 39 .91
CMFP 11 5 10 35 38
Thrombocytopenia
Paclitaxel 98 1 0 0 1 , .0001
CMFP 74 8 6 8 4
Nausea/vomiting
Paclitaxel 63 21 15 1 0 .0032
CMFP 41 34 16 8 0
Mucositis
Paclitaxel 70 19 9 3 0 .0002
CMFP 43 28 22 6 0
Peripheral neuropathy
Paclitaxel 23 37 30 9 1
CMFP 98 2 0 0 0 , .0001
Myalgia/arthralgia
Paclitaxel 27 19 34 20 0
CMFP 95 1 3 1 0 , .0001
Alopecia
Paclitaxel 5 1 18 76 —
CMFP 22 25 28 24 — , .0001
Documented infection
Paclitaxel 95 3 1 1 0 .0006
CMFP 81 6 6 2 5
Fever without documented infection
Paclitaxel 92 3 4 1 0 .0069
CMFP 83 2 6 5 4
*Five untreated patients were omitted.
†The worst WHO grade toxicity each patient experienced.
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In a study by Gianni et al,50 41% of patients with
advanced breast cancer treated with the paclitaxel/doxorubi-
cin combination achieved a complete response, with an
overall objective response rate of 94% and a duration of
response of 11 months for partial responders. Subsequent
phase II studies reported response rates $ 58%.47,51,52 In the
aforementioned randomized ECOG study, the objective
response rate with the paclitaxel/doxorubicin combination
was 47%, with only 6% complete responses and a median
time to progression of 8 months.48 The survival on all three
arms of the ECOG study was similar. In a conflicting
preliminary report, the European Organization for Research
and Treatment of Cancer breast group randomized trial
obtained a better response and time to progression with
single-agent doxorubicin than with paclitaxel monotherapy
but equivalent survival and QOL, with more toxicity re-
ported for the doxorubicin arm.49
The studies by the ECOG and European Organization for
Research and Treatment of Cancer suggest that single-agent
therapy with paclitaxel or doxorubicin with cross-over to the
other agent is as effective as initial combination therapy
when treating metastatic disease, although response rates
and initial time to progression are inferior with monotherapy
compared with the combination. The present study is the
only one of these three in which cross-over to taxane did not
occur, but rather a cross-over to anthracycline on both arms.
Thus, this trial may suggest that the sequence of paclitaxel
and then anthracycline may confer a survival advantage over
the CMFP/anthracycline sequence. This has considerable
implications for optimal sequences in adjuvant studies.
Bonadonna et al53 reported the superiority of sequential
blocks of doxorubicin and CMF in the poor-prognosis
adjuvant setting compared with the cycle-by-cycle alterna-
tion of these two regimens. It has been suggested that the use
of non–cross-resistant alternating chemotherapy is optimal
for cell kill.54-57 Our trial gives further insight into the
optimal sequence of blocks of chemotherapy and suggests
that paclitaxel followed by anthracycline may be a better
sequence of therapy than CMFP followed by anthracycline,
although the initial tumor control is similar. One hypothesis
is that paclitaxel and doxorubicin are less cross-resistant
than CMFP sequences. Thus, there may be optimal se-
quences for new regimens using blocks of chemotherapy,
especially in the adjuvant setting. This hypothesis may be
supported by preliminary results of the Cancer and Leuke-
mia Group B intergroup adjuvant study, which show im-
proved survival with a block of paclitaxel courses after
initial treatment with doxorubicin/cyclophosphamide in node-
positive breast cancer.58 These data require further fol-
low-up and confirmation.
CMFP has been used in debilitated patients who present
with de novo metastatic breast cancer where the aim of
therapy is palliation. This trial shows that paclitaxel is
associated with less myelosuppression and fewer infections
than CMFP, with fewer side effects that require hospitaliza-
tion, equivalent initial tumor control, and, subsequently,
clinically valuable, improved survival.
APPENDIX
Investigators and Data Managers of the Taxol Investigational Trials Group, Australia/New Zealand
The investigators and data managers who participated in this trial were as follows: from Box Hill Hospital, Melbourne: J. Chirgwin, D. Goldstein,
M. Leyden, D. Hopkins, and A. McManus; Dunedin Hospital, New Zealand: M. Jeffery, D. Perez, and F. O’Hagan; Heidelberg Repatriation General
Hospital, Melbourne: W. Cosolo, J. Zalcberg, A. Zimet, and M. D’Astoli; Mater Misericordiae Hospital, Newcastle: S. Ackland, A. Bonaventura, J.
Stewart, J. Killmurray, and S. Freeman; Monash Medical Centre, Melbourne: G. Richardson, S. Hurran, and L. Seferth; Palmerston North Hospital,
New Zealand: S. Allan, G. Forgeson, and G. Humm; Peter MacCallum Cancer Institute, Melbourne: P. Francis, M. Millward, D. Rischin, G. Toner, R.
Maisano, M. Urch, and L. Sheeran; Prince of Wales Hospital, Sydney: B. Brigham, M. Friedlander, C. Lewis, M. Gleason, and E. George; Princess
Alexandra Hospital, Brisbane: E. Walpole, V. Wardle, and A. Karanicolas; Royal Adelaide Hospital, Adelaide: I. Olver, F. Parnis, J. Russell, and N.
Olszewski; Royal Melbourne Hospital, Melbourne: R. Basser, G. Goss, M. Green, and V. Wong; Royal North Shore Hospital, Sydney: D. Bell, J. Levi,
H. Wheeler, and S. McCowatt; Royal Prince Alfred Hospital, Sydney: J. Bishop (study chairman), M. Boyer, A. Coates, M. Tattersall, and A. Childs;
Sir Charles Gairdner Hospital, Perth: M. Buck, M. Byrne, J. Dewar, G. Van Hazel, and L. Donlevy; St Vincent’s Hospital, Sydney: D. Dalley, J.
Grygiel, R. Stuart-Harris, and D. Dalley; Waikato Hospital, New Zealand: I. Kennedy and J. Lee; and Westmead Hospital, Sydney: C. Crombie, H.
Gurney, P. Harnett, R. Kefford, N. Amos, and B. Stuart-Harris.
Table 5. Second-Line Chemotherapy*
Initial Treatment
% Paclitaxel
(n 5 105)
% CMFP
(n 5 99)
Second-line chemotherapy
None 31 31
Anthracycline-based 41 39
CMFP-like 18 12
Taxane 3 6
Other 7 11
*Five patients untreated after initial randomization was omitted.
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Statistical Center (from the Peter MacCallum Cancer Institute, Melbourne): J. Smith (study statistician), J. Dipell, J. Matthews, F. Page, A. Rogers,
and J. Stone.
This trial was sponsored by Bristol-Myers Squibb Company, Princeton, NJ: J. Stephenson (study co-ordinator), J. Williams, N. Onetto, D. Tuck, M.
Dougan, C. Orcutt, and R. Canetta.
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